Scholarlink

<p>Atrial fibrillation (AF) recurrence following radiofrequency ablation (RFA) remains a significant clinical challenge, and pacemaker implantation may influence outcomes. However, the underlying molecular mechanisms are not well understood. This study aimed to investigate whether pacemaker implantation is statistically associated with of AF recurrence and to identify proteomic biomarkers associated with this statistical relationship. We conducted a propensity score-matched cohort study and performed Cox proportional hazards analysis to assess the association between pacemaker implantation and AF recurrence. Exploratory plasma proteomic profiling was performed to identify differentially expressed proteins (DEPs) in a pilot cohort of paroxysmal AF patients with and without pacemakers. An independent validation cohort was used to confirm the findings via Cox analysis and biomarker quantification, followed by statistical mediation analysis. In the discovery cohort, pacemaker implantation was identified as an independent risk factor for post-ablation AF recurrence (adjusted hazard ratio: 2.349, 95% CI: 1.065–5.179, <i>p</i> = 0.034). Exploratory proteomic analysis revealed significantly elevated levels of cartilage intermediate layer protein 1 (CILP1) in pacemaker patients. In the validation cohort, pacemaker implantation remained an independent predictor of AF recurrence, and plasma CILP1 levels were significantly statistically associated with recurrence risk (AUC: 0.737, 95% CI: 0.633–0.842, <i>p</i> = 0.0005). Statistical mediation analysis indicated that elevated CILP1 levels were indirectly associated with the relationship between pacemaker implantation and AF recurrence (<i>p</i> = 0.022). Pacemaker implantation is associated with an increased risk of AF recurrence following RFA. This risk appears to be partially statistically mediated by elevated plasma CILP1 levels. These findings suggest CILP1 may serve as a potential biomarker for AF risk stratification. Given the pilot nature of the proteomic screening, further large-scale studies are warranted to validate these associations.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Pacemaker implantation is associated with post-ablation atrial fibrillation recurrence mediated by plasma CILP1

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年3月20日

查看全文
  • Jingmeng Liu,
  • Taojie Zhou,
  • Changjian Lin,
  • Ning Zhang,
  • Yun Xie,
  • Yue Wei,
  • Qingzhi Luo,
  • Xiang Li,
  • Zimo Sha,
  • Guanhua Wu,
  • Yalan Deng,
  • Tianyou Ling,
  • Wenqi Pan,
  • Lin Lu,
  • Liqun Wu,
  • Qi Jin,
  • Yangyang Bao

摘要

Atrial fibrillation (AF) recurrence following radiofrequency ablation (RFA) remains a significant clinical challenge, and pacemaker implantation may influence outcomes. However, the underlying molecular mechanisms are not well understood. This study aimed to investigate whether pacemaker implantation is statistically associated with of AF recurrence and to identify proteomic biomarkers associated with this statistical relationship. We conducted a propensity score-matched cohort study and performed Cox proportional hazards analysis to assess the association between pacemaker implantation and AF recurrence. Exploratory plasma proteomic profiling was performed to identify differentially expressed proteins (DEPs) in a pilot cohort of paroxysmal AF patients with and without pacemakers. An independent validation cohort was used to confirm the findings via Cox analysis and biomarker quantification, followed by statistical mediation analysis. In the discovery cohort, pacemaker implantation was identified as an independent risk factor for post-ablation AF recurrence (adjusted hazard ratio: 2.349, 95% CI: 1.065–5.179, p = 0.034). Exploratory proteomic analysis revealed significantly elevated levels of cartilage intermediate layer protein 1 (CILP1) in pacemaker patients. In the validation cohort, pacemaker implantation remained an independent predictor of AF recurrence, and plasma CILP1 levels were significantly statistically associated with recurrence risk (AUC: 0.737, 95% CI: 0.633–0.842, p = 0.0005). Statistical mediation analysis indicated that elevated CILP1 levels were indirectly associated with the relationship between pacemaker implantation and AF recurrence (p = 0.022). Pacemaker implantation is associated with an increased risk of AF recurrence following RFA. This risk appears to be partially statistically mediated by elevated plasma CILP1 levels. These findings suggest CILP1 may serve as a potential biomarker for AF risk stratification. Given the pilot nature of the proteomic screening, further large-scale studies are warranted to validate these associations.